The ability of a HTR2B antagonist to prevent PAH by restricting downstream SRC activity (but not phosphorylation) calls into question the inability of receptor tyrosine kinase inhibitors, such as imatinib or nilotinib [42], to effectively treat PAH clinically. This evidence concerns the gene NTRK1 and pulmonary arterial hypertension.